Introduction:

Medical ozone has demonstrated its clinical efficacy as well as the increase of beneficial/risk relationship in rheumatoid arthritis patients treated with metotrexate+ozone combined therapy. At present, gamma-glutamyl transpeptidase is considered as risk indicator of high morbimortality diseases. It has a special value in arthritis diseases due to its pathologic role associated to oxidative stress and in the abnormal bone remodeling processes.

Objective:

Assess the ozone medical effects on gamma-glutamyl transpeptidase levels.

Method:

Patients who suffered of two arthritic diseases: rheumatoid arthritis (n=100; Group treated with Metotrexate (n=50) and metotrexate+ozone (n=50) and knee osteoarthritis (n=40); Group preconditioned with ozone before arthroscopy (n=20) and Group without previous treatment with ozone before arthroscopy (n=20). Rheumatoid arthritis patients were assessed through specific clinic indicators which included antibodies against cyclic citrullinate peptides as well as reduced gluthatione concentrations which are an important endogenous antioxidant.

Results:

Medical ozone regulated serum gamma-glutamyl transpeptidase activity which correlated in inverse proportion to reduced glutathione levels which was the only one redox marker that correlated with all clinical variables (p < 0.05) when patients were treated with metotrexate+ozone.

Conclusion:

Gamma-glutamyl transpeptidase should be considered as biomarker of medical ozone clinical efficacy in rheumatoid arthritis and knee osteoarthritis due to GGT´s both pathologic functions: indicator of oxidative stress and abnormal bone remodeling processes.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )